Although the Democratic Republic of Congo is now experiencing a major outbreak of the disease, two people have been cured of Ebola after using the experimental drugs and were released from a treatment centre in the country's Goma region on Tuesday, according to the BBC.
Since the two successful experimental drugs are accessible by all of Congo's Ebola treatment units, Ryan is hopeful that the development will encourage more of those affected to immediately seek care. Of the four, two treatments known as REGN-EB3 and mAb114 were so effective that researchers announced today they have halted the trial and stopped distributing the others.
Ebola is unsafe but it is curable with correct treatment, said Dr. Jean-Jacques Muyembe, director of Congo's National Institute for Biomedical Research.
"This is great news of course, and this news will save lives and move us closer to finding an effective treatment for Ebola", he said.More news: Huawei Mate 30 & Mate 30 Pro to launch on this date
Four drugs have been trialled on patients suffering from the Ebola virus, with two of these showing very clear signs of improving patients' chances of survival.
So with the current outbreak in Congo, researchers compared ZMapp to three other drugs - Regeneron's compound, the NIH's called mAb114 and an antiviral drug named remdesivir. "This trial is a remarkable advance in the decades-long struggle to respond to Ebola and we appreciate the tremendous efforts of the many governmental and non-governmental organizations who made it possible".
Among the patients admitted with low levels of the Ebola virus detected in their blood, researchers found 94% on REGN-EB3 and 89% on mAb114 survived.
Dr. James Lawler, an infectious disease expert at the University of Nebraska Medical Center who has trained Ebola health workers in Uganda, says it's too soon to say exactly what impact those drugs will have on outbreak response, but agrees that the trial's promising results-and very existence-are an important step forward.
Clinical trials conducted in Congo revealed that there are two novel drugs which are being experimented. "Getting people into care more quickly is absolutely vital", he said.More news: Dave Chappelle Netflix 2019: Will 'Sticks & Stones' tickle amusing bones?
The study began on November 20, 2018 in the Democratic Republic of the Congo (DRC) as part of the emergency response to an ongoing Ebola outbreak in the North Kivu and Ituri Provinces.
This is the 10th outbreak of the disease in the Democratic Republic of the Congo and the most severe in the country since 1976, when scientists identified the deadly virus near the Ebola River.
Scientists said that two experimental treatments are working so well that they will now be offered to all patients in the Democratic Republic of Congo.
A randomized trial started in November a year ago compared four treatments, two of which showed significantly better outcomes than the others.
Both Lawler and Fauci are careful to note that treating already-sick patients is only one part of an effective public-health response. The drugs were developed by using antibodies harvested from Ebola survivors.More news: Samsung May Adopt Graphene Batteries for Phones in 2020
The virus is still spreading in eastern Congo since August 2018 in an outbreak that has become the latest and largest.